公开(公告)号：EP1640022A4

公开(公告)日：2008-08-06

申请号：EP04746565

申请日：2004-06-28

申请人： NIHON PHARMACEUTICAL CO LTD

发明人： HAMAWAKI TOMONORI ,  KATAOKA YOSUKE ,  ISODA TAKAKO

IPC分类号： A61K31/045 ,  A61B1/273 ,  A61B1/31 ,  A61K9/107 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/44 ,  A61K49/00

CPC分类号： A61K49/00 ,  A61B1/2736 ,  A61B1/31 ,  A61K9/1075 ,  A61K31/045 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26 ,  A61K47/44

摘要： It is known that L-menthol controls smooth muscle contraction. In order to use L-menthol in practice as a digestive tract contraction inhibiting agent in digestive tract endoscopy, it is required to devise means of giving a formulation in which an L-menthol-containing formulation remains stable and transparent or little cloudy over a long time after the production and which shows little foaming at the administration. In the present invention, an antifoaming agent is further added to a formulation for inhibiting smooth muscle contraction or a peristaltic contraction in a digestive tract containing a L-menthol emulsion having an average particle size of less than 100nm. Thus, it is possible to obtain a formulation that remains stable over a long time, has a high light transmittance, and produces little foam when filled into a container and sprayed at a target area to inhibit contraction to facilitate observation of the area in endoscopic examination of the digestive tract etc.